Status:
NOT_YET_RECRUITING
Comparison of the Effectiveness of First-line Preventive Treatment of Migraine in Primary Care
Lead Sponsor:
Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Collaborating Sponsors:
Institut Català de la Salut
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Conditions:
Migraine
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study, which is aimed at comparing the effectiveness of the most frequently used drugs in the first line in primary care for the preventive treatment of migraine (amitriptyline, flunarizine, topi...
Eligibility Criteria
Inclusion
- \- Adults (≥18) candidates for preventive treatment for migraine; those with a frequency of ≥4 monthly migraine days, and who agree to participate in the clinical trial.
Exclusion
- People diagnosed with migraine who are not candidates for preventive migraine treatment
- People diagnosed with chronic migraine (\>15 days of headache per month, of which 8 are monthly migraine days)
- Not having a smartphone
- Simultaneous participation in another clinical trial
- Pregnancy or expected pregnancy during the next 3 months
- Lactation
- People with migraine who already receive preventive treatment.
- People on chronic treatment with opioids or other analgesics or NSAIDs that are not used for the symptomatic treatment of migraine, for example, osteoarthritis.
- People who, in the opinion of the clinician, have an absolute contraindication to one of the study drugs or who cannot perform the trial procedures:
- Hypersensitivity to any of the study drugs / Heart block or severe bradycardia / Concomitant treatment with verapamil or diltiazem / Active cardiovascular pathology (recent heart attack, angina, Raynaud's phenomenon) / Major depression or active treatment with antidepressants (including monoamine oxidase inhibitors and St. John's wort) / Other psychiatric illnesses or active treatment with antipsychotics or lithium / Severe liver disease or kidney failure / Parkinson's disease or other extrapyramidal disorders / Epilepsy (diagnosis and/or active treatment) / Any other contraindication that, in the opinion of the clinician, prevents participation in the clinical trial
Key Trial Info
Start Date :
October 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
460 Patients enrolled
Trial Details
Trial ID
NCT06499116
Start Date
October 1 2024
End Date
December 1 2026
Last Update
July 12 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.